Quibim, the Only Healthtech Selected by New York for Its Strategic AI Program

  • Quibim has been chosen as one of just ten companies worldwide to join the NYC AI International Landing Pad, New York City’s flagship program to accelerate high potential artificial intelligence startups.
  • Backed by Anthropic, Lightspeed, Airwallex and Perkins Coie, the initiative will support Quibim’s expansion in the U.S. through strategic connections and access to the city’s innovation ecosystem.

May 11, 2026 — Spanish medical imaging AI company Quibim has been selected as one of ten global startups chosen to join the NYC AI International Landing Pad, the strategic program launched by the City of New York to attract and scale the most promising international AI companies.The initiative, led by Supermomos in partnership with the New York City Economic Development Corporation (NYCEDC), Anthropic, Lightspeed Venture Partners, Airwallex, and Perkins Coie, selected ten companies from seven countries out of hundreds of applicants. All of them represent AI solutions applied to real world critical systems, including healthcare, infrastructure, security, finance, workforce development, and microbiology.

Quibim was recognized for its contribution to healthcare through AI powered medical imaging that enables faster and more accurate disease detection, strengthening its position as one of Europe’s leading advanced healthtech companies. It is the only healthtech globally selected by New York for this strategic AI program.

A strategic initiative to accelerate U.S. market expansion

The NYC AI Landing Pad is a 12 month program designed to help high growth international AI companies establish and scale in New York City. According to the program’s official information, participating companies receive expert mentorship and one on one support from entrepreneurs, AI founders, and investors, along with strategic introductions and direct market access through tailored meetings with potential customers, investors, and talent.

Selected companies become part of New York’s innovation ecosystem, gaining free access for one year to coworking space and a network of more than 35,000 professionals, as well as exclusive events and visibility opportunities. The program also provides support in go to market strategy, fundraising, hiring, and regulatory navigation. It is aimed at companies with proven traction, a clear AI product, and a presence in New York—where Quibim has maintained an office since 2019.

A recognition of Spain’s leadership in health AI

Quibim’s selection places the company—and Spanish innovation in AI driven healthcare—alongside global technology leaders. The program is supported by the New York City Economic Development Corporation (NYCEDC), the public agency responsible for the city’s economic development; Lightspeed, one of the world’s most influential venture capital firms with investments in more than 500 technology companies; Anthropic, creator of Claude, one of the most advanced AI models on the market; Airwallex, a global financial platform built with AI; and Perkins Coie, a leading law firm advising high growth technology companies. Their involvement underscores the program’s relevance and the caliber of the selected companies.

A major opportunity to accelerate U.S. expansion

Participation in the NYC AI Landing Pad will enable Quibim to strengthen its presence in the U.S. market and connect with hospitals, customers, and strategic partners across one of the world’s most dynamic innovation ecosystems. The program provides an ideal environment to accelerate the company’s global growth strategy in AI powered healthcare, offering key connections and specialized support to boost its expansion in the country.

About Quibim

Quibim is a Spanish company that designs pioneering tools to leverage imaging data and improve patient outcomes. With offices in New York (USA), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was founded with the ambition of turning imaging into a catalyst for precision medicine. Quibim leads imaging biomarker research in the life sciences, developing advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company uses MRI, CT, and PET to create regulatory-approved medical devices seamlessly integrated into clinical workflows worldwide. More information at quibim.ai

Quibim Website
Powered by  GDPR Cookie Compliance
Privacy Overview

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.